Activist 13D/13G Filings - Equillium Inc. (EQ)

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime		TypeCompany
Symbol		Filed By
Symbol		Shares Owned
% Owned		Shares Vs. Prev ReportFiling
2024-01-19
06:03 am
Purchase		13GEQUILLIUM INC
EQ		TAKEDA PHARMACEUTICAL CO LTD
TAK		1,842,977
5.2%		1,842,977increase
(New Position)		View
2023-03-03
09:27 am
Sale		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC1,352,210
3.93%		-2,840,444decrease
(-67.75%)		View
2023-01-31
09:41 am
Purchase		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC4,192,654
12.2%		66,987increase
(+1.62%)		View
2022-02-14
11:57 am
Purchase		13GEQUILLIUM INC
EQ		Decheng Capital Management III (Cayman) LLC4,447,308
15.13%		4,447,308increase
(New Position)		View
2022-02-01
12:39 pm
Purchase		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC4,125,667
14.04%		1,327,535increase
(+47.44%)		View
2021-02-16
5:21 pm
Purchase		13DEQUILLIUM INC
EQ		Decheng Capital Global Life Sciences Fund IV L.P.5,733,021
19.7%		5,733,021increase
(New Position)		View
2021-02-03
09:34 am
Purchase		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC2,798,132
11.32%		564,408increase
(+25.27%)		View
2020-02-14
4:05 pm
Sale		13GEQUILLIUM INC
EQ		PFM Health Sciences LP0
0%		-1,361,866decrease
(Position Closed)		View
2020-01-29
12:12 pm
Purchase		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC2,233,724
12.86%		285,431increase
(+14.65%)		View
2019-08-05
1:57 pm
Purchase		13GEQUILLIUM INC
EQ		VICTORY CAPITAL MANAGEMENT INC1,948,293
11.79%		715,704increase
(+58.07%)		View